Clostridium Difficile News and Research RSS Feed - Clostridium Difficile News and Research

Clostridium difficile is a type of bacterium found in human and animal waste. Clostridium difficile is a common cause of diarrhea that occurs in hospitals. It can also cause diarrhea or other intestinal disorders in patients treated with antibiotics.
Johns Hopkins Medicine, Kaiser Permanente partner to expand ways to deliver quality care

Johns Hopkins Medicine, Kaiser Permanente partner to expand ways to deliver quality care

Kaiser Permanente and Johns Hopkins Medicine today announced plans to strengthen the successful collaboration between the two health care organizations. [More]
Expert guidance offers recommendations for hand hygiene in healthcare facilities

Expert guidance offers recommendations for hand hygiene in healthcare facilities

Expert guidance released today offers updated evidence reviews and recommendations for hand hygiene in healthcare facilities. [More]
NIAID launches CRS3123 Phase I trial to treat C. difficile infection

NIAID launches CRS3123 Phase I trial to treat C. difficile infection

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has launched an early-stage clinical trial of CRS3123, an investigational oral antibiotic intended to treat Clostridium difficile (C. difficile) infection. [More]
Fecal transplantation safe, effective for treating C. difficile in immunocompromised patients

Fecal transplantation safe, effective for treating C. difficile in immunocompromised patients

Researchers have found that fecal transplantation is effective and safe for treating C. difficile in immunocompromised patients. This is the result of a study led by Colleen Kelly, M.D., a gastroenterologist in the Center for Women's Gastrointestinal Medicine at The Women's Medicine Collaborative. [More]
Antibiotic treatment for patients who underwent gall bladder removal does not reduce infection risk

Antibiotic treatment for patients who underwent gall bladder removal does not reduce infection risk

Among patients who underwent gall bladder removal for acute calculous cholecystitis, lack of postoperative antibiotic treatment did not result in a greater incidence of infections, according to a study in the July 9 issue of JAMA. [More]
Covenant and Sartori medical centers deploy TRU-D SmartUVC superbug-slaying robot

Covenant and Sartori medical centers deploy TRU-D SmartUVC superbug-slaying robot

Wheaton Franciscan Healthcare-Iowa is the latest to deploy TRU-D SmartUVC, a 5-foot-5 germ-killing ultraviolet robot equipped with the only infection prevention data collection and reporting software on the market. TRU-D is now in use at Covenant Medical Center in Waterloo and Sartori Medical Center in Cedar Falls, Iowa. [More]
Synthetic Biologics supports SYN-004 C.difficile preventative program with formation of Clinical Advisory Board

Synthetic Biologics supports SYN-004 C.difficile preventative program with formation of Clinical Advisory Board

Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today the formation of a Clinical Advisory Board (CAB) to support development of SYN-004, the Company's lead anti-infective product candidate for the prevention of the devastating effects of Clostridium difficile (C. difficile) [More]
Preventing antibiotic side effects: an interview with Florence Séjourné, CEO, Da Volterra

Preventing antibiotic side effects: an interview with Florence Séjourné, CEO, Da Volterra

Like all drugs, antibiotics can have side-effects when administered to people. The most common (and often benign) side effect people experience when taking antibiotics is “associated diarrhea”. This illustrates the fact that antibiotics have an impact on the intestine! [More]
Cubist Pharmaceuticals' SIVEXTRO receives FDA approval for treatment of ABSSSI

Cubist Pharmaceuticals' SIVEXTRO receives FDA approval for treatment of ABSSSI

Cubist Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration approved SIVEXTRO (tedizolid phosphate) for the treatment of adult acute bacterial skin and skin structure infections (ABSSSI). [More]
Fecal microbiota transplantation works by restoring healthy bacteria and functioning to recipient's gut

Fecal microbiota transplantation works by restoring healthy bacteria and functioning to recipient's gut

Fecal microbiota transplantation --- the process of delivering stool bacteria from a healthy donor to a patient suffering from intestinal infection with the bacterium Clostridium difficile --- works by restoring healthy bacteria and functioning to the recipient's gut, according to a study published this week in mBio-, the online open-access journal of the American Society for Microbiology. [More]
C. difficile bacteria pose major health threat without proper infection prevention in hospitals, homes

C. difficile bacteria pose major health threat without proper infection prevention in hospitals, homes

Without proper infection prevention in hospitals, and now homes, the Clostridium difficile bacteria poses a major health threat, cautions a Case Western Reserve University infection control researcher. [More]
Specific enzyme helps protect good commensal bacteria from harmful effects of antibiotics

Specific enzyme helps protect good commensal bacteria from harmful effects of antibiotics

Researchers from Case Western Reserve University in Cleveland have discovered that populating the gastrointestinal (GI) tracts of mice with Bacteroides species producing a specific enzyme helps protect the good commensal bacteria from the harmful effects of antibiotics. [More]
Synthetic, Enterome partner to study effects of beta-lactam antibiotics on gastrointestinal microflora

Synthetic, Enterome partner to study effects of beta-lactam antibiotics on gastrointestinal microflora

Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, and Enterome Bioscience SA, a pioneer in the development of innovative disease management solutions based on a deep understanding of the gut microbiome, today announced that they have entered into an agreement to conduct metagenomic research on the effects of beta-lactam antibiotics on the gastrointestinal microflora (microbiome) of human patients. [More]
Superbugs decrease among patients after adding UVD to cleaning regimen

Superbugs decrease among patients after adding UVD to cleaning regimen

Healthcare-associated vancomycin-resistant enterococcus (VRE), methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile (CD), and other multidrug-resistant organisms (MDRO) were decreased among patients after adding ultraviolet environmental disinfection (UVD) to the cleaning regimen, according to a study published in the June issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC). [More]
Sanofi presents Phase II trial results for investigational vaccine for prevention of CDI

Sanofi presents Phase II trial results for investigational vaccine for prevention of CDI

Sanofi Pasteur, the vaccines division of Sanofi, presented Phase II (H-030-012) trial results for an investigational vaccine for the prevention of Clostridium difficile infection at the 114th General Meeting of the American Society for Microbiology. [More]

Da Volterra presents promising results of DAV-132 compound for prevention of severe C. diff infections

Da Volterra, a leading biopharmaceutical company in the field of bacterial resistance, announces today very promising new results about DAV132 in the prevention of the side effects of antibiotics and the occurrence of severe Clostridium difficile infections. [More]
Luminex announces group B strep as fifth assay planned for launch menu of ARIES

Luminex announces group B strep as fifth assay planned for launch menu of ARIES

Luminex Corporation today announced that Group B Streptococcus (group B strep, GBS) is the fifth assay planned for the launch menu of its new sample-to-answer system, ARIES™. [More]
New expert guidance encourages healthcare institutions to implement prevention efforts infectious diarrhea

New expert guidance encourages healthcare institutions to implement prevention efforts infectious diarrhea

With rates of Clostridium difficile (C. difficile) now rivaling drug-resistant Methicillin-resistant Staphylococcus aureus (MRSA) as the most common bacteria to cause healthcare-associated infections, new expert guidance encourages healthcare institutions to implement and prioritize prevention efforts for this infectious diarrhea. [More]
New report provides in-depth analysis and forecast of global market for HAI products

New report provides in-depth analysis and forecast of global market for HAI products

Reportbuyer.com has added a new market research report: Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products. [More]
Use of frozen stool for fecal transplant successfully treats C. difficile infection

Use of frozen stool for fecal transplant successfully treats C. difficile infection

Using frozen stool from healthy, unrelated donors was safe and effective in treating patients with serious, relapsing diarrhea caused by Clostridium difficile, according to a new pilot study published in Clinical Infectious Diseases and available online. [More]